Selective Response to Omalizumab in a Patient With Concomitant ncMCAS and POTS: What Does it Teach us About the Underlying Disease?
Kacar M, Denman S, Savic S
Department of Clinical Immunology and Allergy, St James's University Hospital, Beckett Street, Leeds, UK
J Investig Allergol Clin Immunol 2018; Vol 28(4)
Key words: Nonclonal mast cell activation syndrome, Postural orthostatic tachycardia syndrome, Omalizumab